DEFM14A: Merck to Acquire Verona Pharma for $107 per ADS

Verona Pharma has entered into a definitive agreement to be acquired by Merck Sharp & Dohme LLC for $107 in cash per American Depositary Share, representing a significant premium to recent trading prices.

Summary

• Verona Pharma plc, a biopharmaceutical company, will be acquired by Merck Sharp & Dohme LLC (Merck) through its wholly-owned subsidiary, Vol Holdings LLC (Bidco).
• The acquisition will be implemented via a court-sanctioned scheme of arrangement under Part 26 of the Companies Act 2006.
• Verona Pharma shareholders will receive $13.375 in cash for each ordinary share, or $107 in cash for each American Depositary Share (ADS), without interest and net of applicable withholding taxes.
• The Verona Board unanimously recommends that shareholders vote FOR the approval of the Scheme of Arrangement and related proposals.
• The total funds necessary for the transaction are approximately $10 billion, which Merck expects to fund through cash on hand, commercial paper, or existing/new credit facilities.
• The transaction is expected to be completed in the fourth quarter of 2025, subject to shareholder approvals, court sanction, and regulatory clearances.
• Outstanding Verona Pharma equity awards (options, RSUs, PRSUs) will be converted into cash payments upon the Effective Time, with unvested awards becoming fully vested (PRSUs at 100% performance or good faith estimate if higher).
• Merck will bear the ADS Cancellation and Distribution Fees in connection with the transaction.

Sentiment

Score: 8

Explanation: The sentiment is highly positive due to the definitive all-cash acquisition at a significant premium, unanimous board recommendation, and fairness opinion from financial advisors. The transaction provides certainty and liquidity to shareholders, outweighing the inherent risks of a standalone biopharmaceutical company. However, potential delays and the loss of future growth opportunities for current shareholders temper the score slightly from a perfect 10.

Positives

• The all-cash nature of the consideration provides liquidity and certainty of value to Verona shareholders, avoiding exposure to future clinical, regulatory, and commercialization risks.
• The ADS consideration of $107 represents a premium of approximately 23% to the closing price of $86.86 per Verona ADS on July 8, 2025.
• The offer also represents a premium of approximately 23% to the 30-day volume-weighted average price ($86.95), 40% to the 60-day VWAP ($76.17), and 50% to the 90-day VWAP ($71.45).
• The Verona Board unanimously recommends the transaction, believing it is in the best interests of the company and its shareholders.
• Centerview Partners LLC provided an oral opinion, subsequently confirmed in writing, that the consideration is fair, from a financial point of view, to the holders of Verona ordinary shares (excluding Excluded Shares).
• The transaction is not conditioned upon Merck obtaining financing, indicating high certainty of funds.
• The Transaction Agreement includes specific performance remedies, ensuring Verona Pharma has recourse if Merck breaches its obligation to close.

Negatives

• Shareholders will not participate in any future earnings or growth of Verona Pharma or benefit from any appreciation in the value of its business or product candidates.
• The transaction may not be completed, leading to significant transaction and opportunity costs, potential disruption to operations, employee attrition, and a negative impact on business relationships.
• Verona Pharma's business operations will be subject to restrictions during the pendency of the transaction, which may limit its ability to pursue new opportunities or respond to market changes.
• Directors and executive officers have financial interests in the transaction (e.g., equity award conversion, severance) that may differ from general shareholder interests.
• Verona Pharma may be required to pay Merck a termination fee of $100 million under certain circumstances if the transaction is not completed.
• The all-cash consideration will be a taxable event for U.S. holders.

Risks

• The transaction may not be completed in a timely manner or at all due to failure to satisfy closing conditions, including shareholder approvals, court sanction, and regulatory clearances.
• Regulatory authorities may impose burdensome conditions or restrictions during antitrust clearance, potentially delaying or abandoning the transaction.
• Shareholder litigation in connection with the transaction may result in significant costs of defense, indemnification, and liability.
• The announcement or pendency of the transaction may impede Verona Pharma's ability to retain and hire key personnel and maintain relationships with customers, distributors, suppliers, or other third parties.
• Management's focus may be diverted from other important business opportunities and operational matters while working to consummate the transaction.
• Failure to complete the transaction could negatively impact Verona Pharma's business, financial results, and the market price of Verona ADSs.
• Verona Pharma's dependence on the successful commercialization of Ohtuvayre and the uncertain market acceptance of Ohtuvayre as a treatment for COPD.
• Risks related to pharmaceutical product development, including ongoing development of ensifentrine and any other product candidates and combinations, and the uncertainty of clinical success.
• The need for additional funding to complete development and commercialization of future product candidates and to continue commercializing Ohtuvayre, with potential delays or elimination of programs if capital cannot be raised.
• Restrictions on operating and financial flexibility due to existing and future indebtedness.

Future Outlook

The transaction is expected to close in the fourth quarter of 2025, after which Verona Pharma will become an indirect wholly-owned subsidiary of Merck, its ADSs will be delisted from Nasdaq, and it will no longer be required to file periodic reports with the SEC. The company's management forecasts significant revenue growth through 2032, driven by Ohtuvayre and ensifentrine programs, before a projected decline in later years.

Management Comments

• The Verona Board considers the terms of the Transaction to be in the best interests of Verona Pharma and its shareholders taken as a whole.
• The Verona Board unanimously recommends that Verona shareholders vote FOR the approval of the Scheme of Arrangement at the Court Meeting; and FOR the approval of both of the resolutions at the General Meeting.
• Verona Pharma's management viewed the revised terms of the acquisition as fair and reasonable, considering the risks and uncertainties of continuing as an independent public company, Centerview's preliminary financial analysis, and the low likelihood of other compelling strategic proposals.

Industry Context

This acquisition represents a strategic move by a global healthcare giant, Merck, to integrate a specialized biopharmaceutical company, Verona Pharma, known for its innovative therapies in chronic respiratory diseases. This aligns with broader industry trends of larger pharmaceutical companies acquiring smaller, innovative firms to expand their pipeline and market presence in specific therapeutic areas, leveraging the acquired company's R&D and early commercialization successes.

Comparison to Industry Standards

• Centerview's selected public company analysis indicated an implied per Verona ADS equity value range of approximately $57.25 to $100.70, based on 2028E EV/Revenue Multiples of 2.5x to 4.5x. The $107 per ADS offer is above this range, suggesting a favorable valuation compared to publicly traded peers.
• Centerview's selected precedent transactions analysis yielded an implied per Verona ADS equity value range of approximately $90.20 to $140.00, based on Four-Year Forward Revenue Multiples of 3.5x to 5.5x. The $107 per ADS offer falls within this range, indicating it is consistent with valuations in comparable M&A deals.
• The 1-day premium of approximately 23% to Verona Pharma's closing price on July 8, 2025, is within the 25% to 85% premium range observed in selected biopharmaceutical transactions, suggesting a competitive offer.
• The 60-day VWAP premium of approximately 40% to Verona Pharma's 60-day VWAP of $76.17 is also within the 35% to 70% premium range from selected precedent transactions, further supporting the fairness of the offer.

Management Changes

Corporate Governance

Legal Proceedings

• Potential shareholder litigation in connection with the Transaction may result in significant costs of defense, indemnification, and liability.
• The Company will promptly advise Merck of any legal proceeding commenced against the Company or its directors/officers relating to the Transaction Agreement and keep Merck informed.

Related Party Transactions

• No current director, officer, or employee of Verona Pharma or its subsidiaries has outstanding indebtedness to the Company or is a party to, or directly or indirectly benefits from, any contract or arrangement with the Company (other than a Plan) that would require disclosure under Item 404 of Regulation S-K, except as disclosed in the filing.

Stakeholder Impact

• Shareholders will receive a fixed cash consideration, providing immediate liquidity and a premium over recent trading prices, but will forgo any future upside potential of Verona Pharma as an independent entity.
• Employees will receive continued base compensation, target short-term cash incentive opportunities, and substantially comparable employee benefits for 12 months post-acquisition, along with severance benefits at least as favorable as existing plans.
• Directors and executive officers will see their equity awards converted to cash, potentially receive severance payments, and benefit from continued indemnification and insurance coverage.
• Customers, distributors, and suppliers may experience changes in relationships or business opportunities due to the change in ownership, though the filing does not detail specific impacts.

Next Steps

• Verona Pharma shareholders to vote on the Scheme of Arrangement at the Court Meeting on September 24, 2025.
• Verona Pharma ordinary shareholders to vote on the Scheme Implementation Proposal and a non-binding advisory proposal on executive compensation at the General Meeting on September 24, 2025.
• Obtain required antitrust clearances (HSR Act waiting period expires September 4, 2025, unless extended).
• Seek sanction of the Scheme of Arrangement by the High Court of Justice of England and Wales, expected in the fourth quarter of 2025.
• Complete the transaction, expected in the fourth quarter of 2025.
• Delist Verona ADSs from Nasdaq and terminate their registration under the Exchange Act after the Effective Time.
• Re-register Verona Pharma as a private company under the Companies Act as soon as reasonably practicable after the closing date.

Key Dates

Recommendation

The unanimous recommendation by the Verona Board and the fairness opinion from Centerview Partners LLC, coupled with the significant premium offered, suggest that the $107 per ADS cash consideration is a favorable outcome for shareholders. Given that this is a definitive all-cash acquisition, the primary action for shareholders is to hold their shares until the transaction closes to receive the cash payment, or sell now to capture the current market price which likely reflects the offer, while avoiding any residual deal risk.

Keywords

Verona Pharma, Merck, Acquisition, Biopharmaceutical, Chronic Respiratory Diseases, Scheme of Arrangement, SEC Filing, M&A, Healthcare, Ohtuvayre, Ensifentrine, Corporate Governance